An Open Label, Randomized Comparison of Femara 2.5mg Once Daily With or Without Weekly Herceptin Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.

Trial Profile

An Open Label, Randomized Comparison of Femara 2.5mg Once Daily With or Without Weekly Herceptin Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2009

At a glance

  • Drugs Letrozole; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms eLEcTRA
  • Most Recent Events

    • 12 Dec 2009 Actual number of patients changed from 93 to 92 according to an abstract from the 32nd Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2009 Results presented at the 32nd Annual San Antonio Breast Cancer Symposium.
    • 11 Aug 2009 Actual patient number (93) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top